{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time to disease progression (TTP) was defined as the time from registration to progression. The median TTP with 95%CI was estimated using the Kaplan Meier method.\n\nProgression was defined as any one or more of the following:\n\nAn increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)","groups":[{"id":"OG000","title":"Sorafenib + Lenalidomide + Dexamethasone"}],"populationDescription":"No participants proceeded to Phase II for evaluation.","reportingStatus":"POSTED","timeFrame":"From registration to progression (up to 3 years)","title":"Time to Disease Progression (Phase II)","type":"SECONDARY"}